O
SYRS

OrbiMed’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

OrbiMed’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-183,750
Closed -$5.99M – 165
2021
Q4 		$5.99M Hold
183,750
– – 0.08% 130
2021
Q3 		$8.21M Hold
183,750
– – 0.09% 137
2021
Q2 		$10M Hold
183,750
– – 0.1% 125
2021
Q1 		$13.7M Buy
183,750
+27,500
+18% +$2.86M 0.13% 111
2020
Q4 		$17M Buy
+156,250
New +$14.3M 0.15% 106

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

OrbiMed's SYRS Position: Q1 2022 in Review

OrbiMed sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2022, closing a stake of 183,750 shares — an estimated $5.99M sold.

OrbiMed first reported a position in SYRS in Q4 2020 and held it in 5 quarters. The position peaked at $17M in Q4 2020. 94 funds tracked by Wall St. Rank hold SYRS as of Q1 2022.

  • OrbiMed reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 183,750 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2022, an estimated $5.99M.
  • OrbiMed first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2020 and held it in 5 quarters.
  • OrbiMed's Syros Pharmaceuticals, Inc. Common Stock position peaked at $17M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.